Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.
- Author:
Hyun Jin KIM
1
Author Information
- Publication Type:Practice Guideline ; Original Article
- Keywords: Cardiovascular diseases; Diabetes mellitus; Glucagon-like peptide-1 receptor agonist; Hypoglycemia; Obesity; Practice guideline
- MeSH: Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2*; Glucagon-Like Peptide 1*; Glucagon-Like Peptide-1 Receptor*; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Obesity; Weight Loss
- From:Journal of Korean Diabetes 2018;19(1):35-40
- CountryRepublic of Korea
- Language:Korean
- Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy, which was a change from the previous guideline that recommended them only as a combination therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) have demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RAs may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
